Altium Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Altium Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-111,000	Closed	-$2.62M	–	92
2023 Q4	$2.62M	Sell	111,000 -689,000	-86%	-$12.3M	1.78%	18
2023 Q3	$11.9M	Buy	800,000 +131,298	+20%	+$1.74M	6.22%	1
2023 Q2	$7.32M	Buy	668,702 +48,702	+8%	+$453K	5.54%	6
2023 Q1	$5.41M	Sell	620,000 -405,000	-40%	-$3.24M	3%	7
2022 Q4	$6.43M	Sell	1,025,000 -725,000	-41%	-$2.76M	3.27%	7
2022 Q3	$6.13M	Hold	1,750,000	–	–	2.25%	6
2022 Q2	$5.16M	Hold	1,750,000	–	–	2.07%	10
2022 Q1	$5.44M	Hold	1,750,000	–	–	1.82%	16
2021 Q4	$5.92M	Buy	+1,750,000	New	+$6.64M	1.63%	14

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Altium Capital Management's CBAY Position: Q1 2024 in Review

Altium Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 111,000 shares — an estimated $2.62M sold.

Altium Capital Management first reported a position in CBAY in Q4 2021 and held it in 9 quarters. The position peaked at $11.9M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Altium Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Altium Capital Management sold 111,000 Cymabay Therapeutics shares in Q1 2024, an estimated $2.62M.
Altium Capital Management first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 9 quarters.
Altium Capital Management's Cymabay Therapeutics position peaked at $11.9M in Q3 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.